Evidence map›Paper›PMID 40685403›Full record

ArticleSignal transduction and targeted therapy2025

Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma.

Jie Qin, Qianyi Gong, Cheng Zhou, Jietian Xu, Yifei Cheng, Weiyue Xu, Di Zhu, Yiming Liu, Yuye Zhang, Yanru Wang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jie Qin *Lab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Qianyi Gong *Lab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Cheng Zhou *Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China.
Jietian Xu *Lab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yifei Cheng *Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China.
Weiyue XuLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Di ZhuLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yiming LiuLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yuye ZhangLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yanru WangLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Lingling GaoLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Lanfang LiLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Wulei HouLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Qian LiLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Binbin LiuLiver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China.
Yazhen ZhuDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Zuoyun WangLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jieyi ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. shi.jieyi@zs-hospital.sh.cn.
Shuangjian QiuLiver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China. qiu.shuangjian@zs-hospital.sh.cn.
Chunmin LiangLab of Tumor Immunology, Department of Human Anatomy, Histology & Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, China. cmliang@fudan.edu.cn.ORCID 0000-0002-6129-9902

Funding

National Natural Science Foundation of China (National Science Foundation of China) 31471147National Natural Science Foundation of China (National Science Foundation of China) 31971111National Natural Science Foundation of China (National Science Foundation of China) 32270886National Natural Science Foundation of China (National Science Foundation of China) 82090053National Natural Science Foundation of China (National Science Foundation of China) U24A20729
6 · The paper itself

Abstract

The treatment of hepatocellular carcinoma (HCC) faces challenges of low response rates to targeted drugs and immune checkpoint inhibitors, which are influenced by complicated microenvironment of HCC. In this study, the complex tumor microenvironment was identified by using tissue microarray (TMA), spatial transcriptomes and single-cell sequencing. High expression of CC chemokine receptor 7 (CCR7) in tumor cells predicted lower Overall Survival (OS). Conversely, CRISPR-Cas9-mediated knockout of CCR7 enhanced the sensitivity of HCC to sorafenib in preclinical experiments, resulting from the inhibition of epithelial-mesenchymal transition through the AKT and ERK signaling pathways. Simultaneously, we revealed CCR7 expression in stromal cells, with increased infiltration of CCR7

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsReceptors, CCR7AnimalsCell Line, TumorChemokine CCL21Epithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMalePrecision MedicineSorafenibTumor MicroenvironmentCCL21 protein, humanCCR7 protein, humanChemokine CCL21Receptors, CCR7Sorafenib

Identifiers

PMID40685403
PMCPMC12277428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.